AI, machine learning offer hope for speeding Alzheimer's development

"Unlearn.AI Inc., of San Francisco, has developed a process to create digital twins of Alzheimer's disease patients in the active-treatment group that predict how they would perform if they weren't given drug. The company's Digenesis process uses historical clinical trial datasets from patients who participated in the control arms of clinical trials to create the twins who are a mash-up of multiple patients in the studies."

Enter your email address to download paper.

Click the link to begin download.
Oops! Something went wrong while submitting the form.
Blog

Digital Twins: A Tool for Risk Mitigation in the Era of COVID-19

Blog

CB Insights 2020 Digital Health 150: Unlearn.AI named in List of Most Innovative Digital Health Startups

Blog

Embracing Innovation to Move Forward

At Unlearn, our goal is to use the data available from historical trials, to generate new evidence to inform and advance research.
Unlearn is thrilled to be recognized as a contributing member of the international community of pioneers in health.
In what ways can we mitigate risk and apply innovative solutions to unstable trials in the wake of COVID-19?